Endothelial dysfunction in children and adolescents with type 1 diabetes mellitus and its role in the development of diabetic peripheral polyneuropathy

Aim.
To measure endothelial factors (nitric oxide (NOx) metabolites, endothelin-1 (ET-1), and basic fibroblast growth factor (bFGF)) in children and adolescentswith diabetes mellitus (DM) during development of diabetic peripheral polyneuropathy (DPNP).
Materials and methods.
A total of 130 children and adolescents with diabetes mellitus were examined. Duration of DM varied from 3 months to 14 years. Thecontrol group comprised 20 children and adolescents without DM or neurologic pathology. Subjective manifestations of DPNP were assessed based on thedata of a standardized Neuropathy Symptom Score (NSS) questionnaire. Neuropathy Disability Score (NDS) questionnaire was used to monitor objectivechanges of DPNP. NOx metabolites were detected with Griess reagent (Aldrich Chemical Co, USA). Serum ET-1 and bFGF were measured using solid-phaseimmunoenzyme assay (DRG, USA) and CYTIMMINE (USA) kits respectively.
Results.
All children and adolescents with DM1 had lower NOx and bFGF levels than controls. ET-1 level in DM patients was 3.5 times that in controls. DMpatients with DPNP had more pronounced endothelial dysfunction than DM patients without DPNP and control subjects. Patients with hyperproduction ofNOx had DM for more than 10 years and their total NDS score was significantly higher than in two other groups.
Conclusion.
Endothelial dysfunction in children and adolescents with type 1 diabetes mellitus progresses with the development of DPNP. Depletion of endothelialfunctional reserve is responsible for the unfavourable course of DPNP.

endothelial dysfunction, children, adolescents, type 1 diabetes mellitus, diabetic peripheral polyneuropathy

1. Дедов И.И., Кураева Т.Л., Петеркова В.А., Щербачева Л.Н. Сахарный диабет у детей и подростков. - М.: Универсум Паблишинг, 2002. С. 391.

2. Thomas P.K. Diabetic peripheral neuropathies: their cost to patient and society and the value of knowledge of risk factors for development of interventions. - Eur. Nenrol. 1999; V.41: 35-43.

3. Галстян Г.Р. Хронические осложнения сахарного диабета: этиопатогенез, клиника, лечение. - Русский мед. журнал. 2002; 27: 1266-1269.

4. Сахарный диабет. Руководство для врачей. - Под ред. И.И. Дедова, М.В. Шестаковой. - М.: Универсум Паблишинг, 2003. С. 450.

5. Смирнова О.М. Оксидативный стресс и возможности предотвращения его развития. - Диабетон. 1999; 19-25.

6. Cerielo A. Патофизиологические механизмы сосудистых осложнений при сахарном диабете: роль окислительного стресса. - Медикография. 2000; 62: c. 25-28.

7. Stevens M.I., Feldman E.L., Green D.A. The aetiology of diabetic neuropathy: the combined role of metabolic and vascular defects. - Diabetic Medicine. 1995; V.12: 566-579.

8. Dyck P.J., Thomas P.K. Diabetic Neuropathy // 2-nd Edd.: Philadelphia, 1999. - 265p.

9. Ribera J., Marsal J., Casanovas A. et al. Nitric oxide synthase in rat Neuromuscular junction and in nerve terminals of Torpedo electric organ: its role as regulator of acetylcholine re-lease. - J. Neurosci. Res. 1998; V.51: 90-102.

10. Rask-Madsen C., King G.L. Proatherosclerotic Mechanisms Involving Protein Kinase C in Diabetes and Insulin Resistance. - Arteriosclerosis, Thrombosis, and Vascular Biology. 2005; V.25: 487.

11. Almhanna K., Wilkins P.L., Bavis J.R. et al. Hyperglycemia triggers abnormal signaling and proliferative responses in Schwann cells. - Neurochem. Res. 2002; V.27 (N 11): 1341-1347.

12. Malik R.A., Tesfaye S., Newrick P.G. et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. - Diabetologia. 2005; V.48 (N 3): 578-585.

13. Sima A.A. New insights into the metabolic and molecular basis for diabetic neuropathy. - Cell Mol. Life Sci. 2003; V.60; 2445-2464.

14. Song B., Vinters H. V., Wu D., Pardridge W.M. Enhanced Neuroprotective Effects of Basic Fibroblast Growth Factor in Regional. - Brain Ischemia after Conjugation to a Blood-Brain Barrier Delivery Vector. 2002; V.301 (N 2): 605-610.